AMICUS THERAPEUTICS, INC. - Common Stock (FOLD)

Historical Holders from Q1 2014 to Q3 2025

Symbol
FOLD on Nasdaq
CUSIP
03152W109
Type / Class
Equity / Common Stock
Shares outstanding
309M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
312M
Holdings value
$2.46B
% of all portfolios
0.005%
Grand Portfolio weight change
0%
Number of holders
281
Number of buys
153
Number of sells
-124
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AMICUS THERAPEUTICS, INC. - Common Stock (FOLD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 10% $274M 30.9M The Vanguard Group Nov 28, 2025
WELLINGTON MANAGEMENT GROUP LLP 9.5% $214M 28.5M Wellington Management Group LLP Dec 31, 2024
BlackRock, Inc. 7.4% -21.1% $171M -$38.6M 22.8M -18.4% BlackRock, Inc. Mar 31, 2025
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 5.2% +6% $126M $9.42M 16M +8.09% WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Sep 30, 2025
Avoro Capital Advisors LLC 4.87% -26.1% $118M -$43.1M 15M -26.7% Avoro Capital Advisors LLC Sep 30, 2025
Redmile Group, LLC 4.6% $107M 14.2M Redmile Group, LLC Dec 31, 2024
PERCEPTIVE ADVISORS LLC 2.4% -65.7% $43.3M -$82.1M 7.41M -65.5% Perceptive Advisors LLC Jun 30, 2025

Institutional Holders of AMICUS THERAPEUTICS, INC. - Common Stock (FOLD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 312M $2.46B -$41.6M $7.88 281
2025 Q2 319M $1.83B +$26.5M $5.73 268
2025 Q1 309M $2.53B +$26.4M $8.16 280
2024 Q4 305M $2.87B -$29.1M $9.42 285
2024 Q3 307M $3.28B -$104M $10.68 287
2024 Q2 315M $3.13B -$32.3M $9.92 255
2024 Q1 317M $3.74B -$30.9M $11.78 250
2023 Q4 314M $4.45B +$296M $14.19 227
2023 Q3 291M $3.54B -$125M $12.16 225
2023 Q2 307M $3.85B +$126M $12.56 211
2023 Q1 297M $3.3B +$67M $11.09 221
2022 Q4 292M $3.56B +$4.96M $12.21 224
2022 Q3 292M $3.05B -$137M $10.44 218
2022 Q2 305M $3.28B +$28M $10.74 200
2022 Q1 303M $2.87B +$16.6M $9.47 201
2021 Q4 301M $3.48B +$96.4M $11.55 216
2021 Q3 293M $2.8B +$154M $9.55 225
2021 Q2 277M $2.67B +$6.81M $9.64 224
2021 Q1 276M $2.72B -$231M $9.88 242
2020 Q4 279M $6.44B +$42.6M $23.09 269
2020 Q3 278M $3.92B -$60.3M $14.12 238
2020 Q2 281M $4.24B +$7.01M $15.08 215
2020 Q1 283M $2.62B +$72.5M $9.24 193
2019 Q4 275M $2.68B +$17M $9.74 210
2019 Q3 273M $2.19B +$7.54M $8.02 195
2019 Q2 269M $3.35B +$246M $12.48 203
2019 Q1 251M $3.41B +$283M $13.60 200
2018 Q4 231M $2.21B +$14.1M $9.58 183
2018 Q3 228M $2.76B -$4.7M $12.09 199
2018 Q2 226M $3.54B +$30.8M $15.62 200
2018 Q1 225M $3.38B +$287M $15.04 199
2017 Q4 206M $2.96B +$69.1M $14.39 184
2017 Q3 198M $2.99B +$374M $15.08 186
2017 Q2 174M $1.75B +$127M $10.07 145
2017 Q1 169M $1.2B +$168M $7.13 134
2016 Q4 157M $780M +$23.5M $4.97 132
2016 Q3 148M $1.1B +$112M $7.40 134
2016 Q2 137M $748M -$24.9M $5.46 124
2016 Q1 140M $1.18B +$5.18M $8.45 127
2015 Q4 139M $1.35B +$33.6M $9.70 136
2015 Q3 128M $1.76B +$201M $13.99 144
2015 Q2 114M $1.61B +$453M $14.15 137
2015 Q1 82.3M $892M +$46.4M $10.88 127
2014 Q4 79.6M $662M +$233M $8.32 108
2014 Q3 47M $280M +$43.1M $5.95 94
2014 Q2 40.7M $136M +$27.2M $3.34 60
2014 Q1 34.3M $71M -$324K $2.07 67